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Abstract
Transforming growth factor-β (TGF-β) is a potent inhibitor of cell proliferation. This study
investigated whether overexpression of Smad7, which blocks TGF-β–induced activation of Smad2/3,
could prevent the suppression of regeneration of small-for-size liver grafts. Rats were intravenously
given adenoviruses (2 × 109 pfu/rat) carrying the LacZ gene or the Smad7 gene (Ad-Smad7) 3 days
prior to liver harvesting. Half-size livers were implanted into recipients of the same weight or twice
the donor weight, and this resulted in half-size or quarter-size liver grafts. Cell proliferation, detected
by 5-bromo-2′-deoxyuridine (BrdU) incorporation, increased to 23% in half-size grafts at 38 hours
after implantation but was only 4% in quarter-size grafts. Graft weight did not increase after 38 hours
in full-size and quarter-size grafts but increased 28% in half-size grafts. Ad-Smad7 restored BrdU
labeling to 32%, and the graft weight increased to 43% in quarter-size grafts. Serum total bilirubin
increased approximately 30-fold after the implantation of quarter-size grafts. Ad-Smad7 blunted
hyperbilirubinemia by 80%. The basal hepatic TGF-β1 level was 7 ng/g of liver wet weight, and this
increased to 30 ng/g at 1.5 hours after the transplantation of full-size grafts but decreased rapidly
afterwards. After the transplantation of quarter-size grafts, however, TGF-β1 progressively increased
to 159 ng/g in 38 hours. Nuclear phosphorylated Smad2/3 was barely detectable, and p21Cip1
expression was negligible in full-size grafts but increased markedly in quarter-size grafts. Ad-
Smad7 blocked Smad2/3 activation and expression of p21Cip1. Together, these data show that TGF-
β is responsible, at least in part, for the defective liver regeneration in small-for-size grafts by
activating the Smad signaling pathway.
Living donor and split liver transplantation (LT) has become more widely used in recent years
to alleviate the mortality resulting from the scarcity of suitable liver grafts for transplantation.
1,2 Donor-recipient graft size disparity leading to small-for-size graft dysfunction and failure
is an important issue limiting the wider use of partial LT for adults.3 The mechanisms
underlying the dysfunction and failure of small-for-size grafts remain unclear. Previous studies
have indicated that liver regeneration is markedly suppressed in small-for-size liver grafts, and
this appears to contribute to graft failure.4–6
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Growth factors such as hepatic growth factor (HGF), transforming growth factor-α (TGF-α),
epidermal growth factor (EGF), and vascular endothelial growth factor and the cytokines
interleukin-6 (IL-6) and tumor necrosis factor-α (TNFα) stimulate liver regeneration.7–9 TGF-
β is a potent inhibitor of hepatocyte proliferation that counterbalances the stimulatory effects
of mitogens during liver regeneration.10–12 In many cell types, TGF-β is the most potent
growth-inhibitory polypeptide currently known.13 However, whether TGF-β plays a role in
the suppression of small-for-size liver graft regeneration remains unclear.
TGF-β elicits its biological effects by signaling through a heteromeric receptor complex
consisting of type I and type II receptors. The binding of TGF-β to type II receptors leads to
the recruitment, phosphorylation, and activation of type I receptors, which subsequently
phosphorylate proteins of the Smad family, particularly Smad2 and Smad3.14,15
Phosphorylated Smad2 and Smad3 form a complex with Smad4, move into the nucleus, and
activate target genes expressing regulatory proteins for cell proliferation, differentiation, and
cell death.14,16 TGF-β also regulates mitogen-activated protein kinase–mediated signaling
pathways and other signaling proteins, such as protein kinase A, protein kinase C,
phospholipase C, and nuclear factor-κB, in different cell types.17,18
Another Smad family member, Smad7, associates stably with the TGF-β receptor complex,
which inhibits TGF-β–induced phosphorylation of Smad2 and Smad3 and blocks TGF-β–
dependent signaling.19 This study examined the effect of the adenoviral delivery of Smad7 on
liver regeneration after LT with small-for-size grafts. Our results show that TGF-β1 increases
sharply after the transplantation of small-for-size liver grafts in association with Smad2/3
phosphorylation and nuclear translocation. Smad7 adenoviral expression blocks Smad2/3
activation, promotes liver regeneration, and improves graft function.
MATERIALS AND METHODS
Animals and LT
A recombinant adenovirus containing the transgene for either β-galactosidase (Ad-LacZ) or
human Smad7 (Ad-Smad7) was prepared at the University of North Carolina as described
previously.20 Ad-LacZ, which contains the β-galactosidase gene driven by the cytomegalovirus
promoter, was used as a control viral vector. The Ad-Smad7 virus expresses a C-terminal
hemagglutinin (HA)-tagged human Smad7 protein. The human Smad7 complementary DNA
was obtained from Dr. Wrana (Hospital for Sick Children, Toronto, Canada) and cloned into
the pGI-AdCMV5 transfer vector (Qbiogene, Carlsbad, CA). Viral amplification was
performed in 293 cells and cesium chloride purified by the standard methodology. Viral titer
estimates were performed by optical density measurements. The virus (2 × 109 pfu) was diluted
in 0.5 mL of normal saline and injected into the tail vein of donor rats (male Lewis rats, 170–
200 g). In preliminary studies from this laboratory, the infection rates of liver cells were over
80% when doses of adenovirus ranging from 1 to 3 × 109 pfu were used.
Our previous studies showed that adenoviral protein expression peaks in 2 to 3 days and persists
for about 3 weeks.21 Therefore, 3 days after the viral infection, livers were explanted and
reduced in size by the removal of the left lateral lobe, the left portion of the median lobe, and
the anterior and posterior caudate lobes ex vivo as described.5 This procedure decreased liver
mass by approximately 50%.22 Explants were stored in University of Wisconsin solution at 0
to 1°C for 6 hours and rinsed with lactated Ringer’s solution (Abbott Laboratories, North
Chicago, IL) just prior to implantation.
Reduced-size liver explants were implanted into recipients of similar (170–200 g) or greater
body weights (350–430 g), and this resulted in graft weight/standard liver weight (defined as
4% of body weight) values of approximately 50% (half-size) and approximately 25% (quarter-
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size), respectively.23 Unreduced livers were implanted into recipients of similar body weights
(170–200 g) as full-size controls. The hepatic artery and the bile duct were anastomosed with
intraluminal splints. Implantation procedures usually took about 50 minutes. For sham
operations, the abdominal wall was opened, and ligaments around the liver were freed. The
abdominal wall was then closed with running sutures after 50 minutes. Under these conditions,
survival was 100% for full-size grafts, 80% for half-size grafts, and 30% for quarter-size grafts.
23 The graft weight/standard liver weight values were on average 24.9% ± 6% in the quarter-
size group pretreated with saline, 26.1% ± 4% in the quarter-size group treated with Ad-
LacZ, and 26.0% ± 3% for the quarter-size grafts treated with Ad-Smad7 (P > 0.10 versus the
saline-pretreated and Ad-LacZ–pretreated quarter-size groups). The graft weight was measured
just prior to cold storage and after harvesting at various times after implantation. All animals
were given humane care in compliance with institutional guidelines using protocols approved
by the Institutional Animal Care and Use Committee.
Bilirubin
Blood samples were collected from the tail vein at 18, 24, and 38 hours after implantation.
Total bilirubin in sera was determined with analytical kits from Pointe Scientific (Uncoln Park,
MI) to assess liver function.
Immunohistochemical Staining for 5-Bromo-2′-Deoxyuridine (BrdU), Proliferating Cell
Nuclear Antigen (PCNA), Phosphorylated Smad2/3, and β-Galactosidase
BrdU was injected intraperitoneally (100 mg/kg) 1 hour prior to liver harvesting to detect cells
synthesizing DNA. At 38 hours after implantation, livers were harvested, and BrdU
incorporation and expression of PCNA, another marker of cell proliferation, were determined
immunohistochemically in liver sections as described elsewhere.5 Cells positive and negative
for BrdU and PCNA were counted in 10 randomly selected fields under a light microscope
with a 20× objective lens. Immunohistochemistry of phosphorylated Smad2/3, Ski-like
oncogene (SnoN), and β-galactosidase was performed with primary antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA) at a concentration of 1:200 for 1 hour, 1 hour, and 20 minutes
at room temperature, respectively. Phosphorylated Smad2/3-positive and Smad2/3-negative
cells were counted in 10 randomly selected fields under a light microscope with a 40× objective
lens.
Western Blotting
Livers were harvested, snap-frozen in liquid nitrogen, homogenized in a buffer containing 40
mM trishydroxymethylaminomethane (pH 7.6), 140 mM NaCl, and 1% protease and
phosphatase inhibitor cocktails (Sigma, St. Louis, MO), and centrifuged at 1000g for 10
minutes at 4°C. The supernatant was analyzed for HA protein, Smad7, SnoN, p21Cip1,
p27Kip1, p15Ink4B, p16Ink4A, and tumor protein p53 (p53) by western blotting6 using
specific antibodies against the proteins of interest (Santa Cruz Biotechnology) at a dilution of
1:300 to 1:500 at 4°C overnight followed by incubation with an appropriate secondary antibody
at 1:1000 to 1:3000 for 1 hour. Chemiluminescence was detected with an ECL Plus western
blotting detection system (Amersham Biosciences, Little Chalfont, United Kingdom). To
confirm equal loading, blots were reprobed with anti-actin primary antibody at 1:3000 for 1
hour (ICN, Costa Mesa, CA). The protein concentration was determined with the Bio-Rad
protein assay (Bio-Rad, Hercules, CA).
Detection of TGF-β1 in Liver Tissue
Liver tissue was collected into liquid nitrogen, stored at −80°C, and homogenized after thawing
in a buffer (pH 7.5) containing 20 mM trishydroxymethylaminomethane, 0.25 M sucrose, 2
mM ethylene diamine tetraacetic acid, 10 mM ethylene glycol tetraacetic acid, 1% Triton
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X-100, and 1% protease inhibitor cocktail (Sigma). The homogenates were centrifuged at
100,000g at 4°C for 1 hour. Total TGF-β1 in the supernatant, including both precursor and
biologically active cleaved forms, was determined with a TGF-β1 Emax immunoassay system
from Promega (Madison, WI) according to the manufacturer’s instructions.
Statistical Analysis
All groups were compared with an analysis of variance or Kruskal-Wallis test as appropriate.
Numbers in each group for different parameters are shown in the figure legends. Differences
were considered significant at P < 0.05.
RESULTS
TGF-β1 Increased in Small-For-Size Liver Grafts
TGF-β is a potent inhibitor of cell proliferation. Accordingly, we measured total TGF-β1 in
livers before and after LT. Before LT, TGF-β1 was 7 ng/g of liver wet weight. After full-size
LT, TGF-β1 increased to 30 ng/g at 1.5 hours but decreased afterwards to close to pre-transplant
levels at 38 hours after the operation (Fig. 1). After the transplantation of half-size grafts, a
progressive increase of TGF-β1 occurred with a maximum of 79 ng/g of liver at 18 hours, and
it then declined gradually. An even larger sustained increase occurred after the transplantation
of quarter-size grafts, with TGF-β1 levels rising to 143 ng/g after 18 hours and to 159 ng/g
after 38 hours (Fig. 1).
Expression of β-Galactosidase and HA Protein in the Liver After Viral Gene Delivery
Rats were infected with Ad-LacZ, which carries the gene for β-galactosidase. At 3 days after
infection with Ad-LacZ, over 80% of hepatocytes expressed β-galactosidase (Fig. 2A, right).
By contrast, β-galactosidase was not detectable in livers from rats receiving normal saline (Fig.
2A, left). These results indicate that the adenovirus effectively infects liver cells.
The Ad-Smad7 virus expresses a C-terminal, HA-tagged human Smad7 protein. The HA tag
is a general epitope tag in expression vectors and does not interfere with the bioactivity or
biodistribution of recombinant proteins. The HA tag is present only in the Smad7 proteins
encoded by the Smad7 gene carried by the adenoviral vector. Therefore, detection of the HA
tag indicates expression of the Smad7 gene transfected by adenoviral vectors. The HA tag was
not detectable by western blotting in livers from rats given saline (Fig. 2B). By contrast, livers
from rats infected with Ad-Smad7 showed high levels of the HA tag, indicating Smad7 protein
expression (Fig. 2B). We also detected Smad7 expression by western blotting. Smad7 was
barely detectable in livers from saline-treated rats but increased overtly in livers from rats
infected with Ad-Smad7 (Fig. 2B). Therefore, this Smad7 expression is possibly mainly due
to gene transfection.
Liver Regeneration Was Suppressed After the Transplantation of Small-for-Size Liver Grafts:
Reversal by Smad7
Liver regeneration was evaluated by BrdU incorporation, expression of PCNA, and increases
in graft weight. Our previous studies showed that after the implantation of half-size livers,
BrdU labeling first increased at about 18 hours postoperatively in both periportal and midzonal
regions of the liver lobule and was maximal after 38 hours. Proliferating cells were
predominantly hepatocytes.5
In this study, cell proliferation was assessed at 38 hours after implantation. The concentration
of BrdU-positive cells was about 0.2% in livers from Ad-LacZ–treated mice after a sham
operation (Fig. 3, upper left, and Fig. 4A), which was not different from that for saline-treated
rats after a sham operation (data not shown). After Ad-LacZ treatment and LT, BrdU labeling
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increased to 2.5% and 23%, respectively, in full-size and half-size grafts (Fig. 3, upper right
and middle left, and Fig. 4A). By contrast, in quarter-size grafts, BrdU labeling was only 2%
and 4% after saline and Ad-LacZ treatment, respectively, and this indicated suppression of cell
proliferation in small-for-size liver grafts (P < 0.001 versus half-size grafts; Fig. 3, middle right
and lower left, and Fig. 4A). Adenoviral expression of Smad7, which blocks the TGF-β/Smad
signaling, restored cell proliferation in quarter-size grafts to 32% (Fig. 3, lower right, and Fig.
4A).
PCNA was used as another indicator of cell proliferation. PCNA increased from 0.1% after a
sham operation to 2.0% and 7.0% after the transplantation of full-size and half-size grafts,
respectively, from Ad-LacZ–treated donors (Fig. 4B). By contrast, PCNA expression was 0.2%
and 0.4% in quarter-size grafts after saline and Ad-LacZ treatment, respectively (Fig. 4B). Ad-
Smad7 donor treatment increased PCNA expression markedly in quarter-size grafts to 16.6%
(Fig. 4B).
Increases in the graft weight reflect both the proliferation and hypertrophy of liver cells. Thirty-
eight hours after implantation, the graft weight did not increase in full-size grafts infected with
Ad-LacZ but increased by 28% in half-size grafts infected with Ad-LacZ (Fig. 4C). After
quarter-size transplantation, the graft weight did not increase in grafts pretreated with either
saline or Ad-LacZ (Fig. 4C). However, after infection with Ad-Smad7, the weight of quarter-
size grafts increased by 43%, and this indicates that inhibition of TGF-β/Smad signaling
reverses the suppression of regeneration of small-for-size liver grafts (Fig. 4C).
Smad7 Expression Improved the Function of Small-for-Size Liver Grafts
The improvement of liver regeneration should enhance the recovery of liver function.
Hyperbilirubinemia indicates poor liver function. Therefore, total bilirubin was measured after
LT. Prior to LT, the serum bilirubin level was on average approximately 0.1 mg/dL. At 38
hours after full-size and half-size LT, bilirubin did not increase significantly (Fig. 5 and data
not shown). By contrast, bilirubin increased more than 30-fold in rats receiving quarter-size
liver grafts pretreated with saline or Ad-LacZ, and this indicated poor liver function (Fig. 5).
Pretreatment of liver donors with Ad-Smad7 decreased peak bilirubin by 80% after quarter-
size LT (Fig. 5). With Ad-Smad7 treatment, the total bilirubin level after the transplantation
of quarter-size grafts was not statistically different from that of full-size grafts (Fig. 5).
Ad-Smad7 Blocked Nuclear Translocation of Phosphorylated Smad2/3 in Small-for-Size
Liver Grafts
Activation of TGF-β receptors leads to phosphorylation and nuclear translocation of Smad2
and Smad3, thus activating target genes that negatively regulate the cell cycle.14,16 Therefore,
nuclear translocation of phosphorylated Smad2/3 was assessed. After a sham operation and
full-size LT, phosphorylated Smad2/3 in nuclei of hepatocytes was barely detectable (median
= 0.43% and median = 0.42%, respectively, n = 4 per group) by immunocytochemistry (Fig.
6A, upper left and right). In half-size grafts, a few hepatocytes (median = 2.4%, n = 4, P < 0.05
versus full-size grafts by the Kruskal-Wallis test) showed phosphorylated Smad2/3 in their
nuclei (Fig. 6A, middle left). By contrast, after the transplantation of saline-treated or Ad-
LacZ–treated quarter-size liver grafts, phosphorylated Smad2/3 increased markedly in nuclei
of many hepatocytes at 18 hours (data not shown) and 38 hours after the operation (Fig. 6A,
middle right and lower left; median = 33.8% and median = 33.1%, respectively, n = 4 per
group, P < 0.05 versus full-size grafts by the Kruskal-Wallis test). Importantly after the
pretreatment of donors with Ad-Smad7, nuclear phosphorylated Smad2/3 decreased
substantially to 1.8% in hepatocytes (Fig. 6A, lower right; n = 4 per group, P < 0.05 versus
quarter-size grafts with Ad-LacZ treatment by the Kruskal-Wallis test).
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SnoN exerts negative control over TGF-β signaling by interaction with Smads. Overexpression
of SnoN inhibits certain TGF-β–inducible signals.24 Therefore, we also investigated SnoN
expression by western blotting. A basal level of SnoN expression was observed in livers from
sham-operated rats (Fig. 6B, n = 4). After transplantation, SnoN expression was slightly
increased in full-size and half-size grafts (n = 4 per group) but dramatically increased in quarter-
size grafts treated with saline or transfected with Ad-LacZ (n = 4 per group). In quarter-size
grafts transfected with Ad-Smad7 (n = 4), expression of SnoN was decreased to almost the
basal level, possibly because of inhibition of TGF-β–induced up-regulation of SnoN. Detection
of nuclear SnoN by immunohistochemical staining showed a similar pattern of alterations (data
not shown). Therefore, Ad-Smad7 does not exert its effects by increasing nuclear SnoN.
p21Cip1 Expression Increased After the Transplantation of Small-For-Size Liver Grafts:
Prevention by Ad-Smad7
Cyclins regulate the cell cycle in association with cyclin-dependent kinases (CDKs), which
are under the inhibitory control of cyclin-dependent kinase inhibitors (CDKIs).25,26
Antiproliferative effects of TGF-β in some cell types are mediated by CDKIs.18,27,28
Therefore, we investigated whether CDKIs are involved in Smad2/3-mediated TGF-β’s
antiproliferative effects in small-for-size liver grafts. p21Cip1, a universal inhibitor of CDKs,
was barely detectable by western blotting in sham-operated livers and full-size liver grafts (Fig.
7A,B). After the transplantation of quarter-size grafts, p21Cip1 increased markedly at 18 hours
(data not shown) and remained more than 28-fold–elevated at 38 hours (Fig. 7A,B). After
inhibition of TGF-β/Smad signaling by Ad-Smad7, expression of p21Cip1 was blunted by 60%
(Fig. 7A,B). By contrast, the CDKIs p27Kip1 and p15Ink4B were not significantly different
between sham-operated livers, full-size grafts, and quarter-size grafts (Fig. 7A), and the CDKI
p16Ink4A was not detectable in any group (data not shown).
In some cells, p21Cip1 can be induced by a p53-dependent mechanism following stress.18
Accordingly, we measured p53 after LT. Although p21Cip1 was markedly higher in quarter-
size grafts compared to full-size grafts, p53 was not different between sham-operated livers,
full-size grafts, and quarter-size grafts (Fig. 7A). Therefore, p21Cip1 changes in small-for-size
grafts did not appear to be occurring in a p53-dependent manner.
DISCUSSION
TGF-β/Smad Signaling Plays an Important Role in the Suppression of Liver Regeneration in
Small-for-Size Liver Grafts
Survival and functional recovery of liver grafts after partial LT depend highly on liver
regeneration. Unfortunately, liver regeneration is suppressed in small-for-size liver grafts,4–
6,29 and this prevents or delays the recovery of liver mass and function after partial LT. As a
result, the small grafts can experience excessive metabolic burden and eventually fail.
Therefore, promotion of liver regeneration is of clear benefit for improving the outcome of
small-for-size LT. Why small-for-size liver grafts fail to regenerate is not fully understood.
Our previous study showed that repopulation of stem cells appears not to play an important
role in liver regeneration after partial LT in rats, at least in early stages, and thus the mechanisms
suppressing regeneration after quarter-size LT are acting on hepatocytes rather than stem cells.
5
Liver regeneration is a complex, multistep process. In the early stage of regeneration, a variety
of cytokines (eg, IL-6 and TNFα) and hormones are released, transcription factors and kinases
are activated, and immediate-early genes are expressed.7,8 This activation of the immediate-
early genes and transcription factors is usually neither specific nor sufficient to cause liver
regeneration. However, they prepare the liver for regeneration. Such priming makes
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hepatocytes responsive to growth factors (eg, HGF, EGF, heparin-binding EGF, and
amphiregulin)7,30,31 which stimulate progression of the cell cycle.7–9 Early signaling events
lead to activation of secondary or delayed gene responses (eg, expression of cyclins and
activation of cyclin kinases) and progression of the cell cycle. Other cytokines and factors,
such as TGF-β, CDKIs, retinoblastoma proteins, suppressor of cytokine signaling-3, and the
p53 gene, inhibit proliferation responses.7 Appropriate regeneration requires orchestrated
functions of different elements not only in appropriate amounts but also at the appropriate
location and time.
After living donor LT, serum HGF and TGF-β increase.32,33 HGF, TNFα, and IL-6 also
increase after partial LT in rodents.5,34 These major regenerative cytokines and growth factors
are higher in quarter-size liver grafts that fail to regenerate than in half-size grafts that
regenerate rapidly.5 Therefore, inhibition of regeneration in quarter-size grafts is unlikely due
to insufficiency of proregenerative HGF, TNFα, and IL-6 formation.5 Rather, suppression of
regeneration of small-for-size liver grafts is associated with inhibition of proliferative c-Jun
N-terminal kinase and activating protein-1 activation at an early stage after LT.5 Because the
speed of the regenerative responses depends on a balance of proliferative and inhibitory factors,
in this study, we further investigated whether TGF-β signaling is involved in the suppression
of small-for-size liver graft regeneration.
TGF-β is a potent growth inhibitor in a variety of cell types.8,10,18,35 After the transplantation
of quarter-size grafts, TGF-β1 increased dramatically at 18 hours after the operation and
remained elevated for at least 38 hours (Fig. 1). This higher and sustained increase of TGF-
β1 was associated with suppression of regeneration, and this suggests that TGF-β may play an
important role in the inhibition of regeneration (Fig. 3 and Fig. 4). Reactive oxygen species,
which increase dramatically in failing small-for-size liver grafts,23 enhance the synthesis and
activation of TGF-β.36,37 Therefore, it is not surprising that TGF-β increases to a greater extent
in small-for-size liver grafts.
Two major signaling cascades mediate the biological and pathological effects of TGF-β,
namely, the Smad and Ras/mitogen-activated protein kinase pathways.18 Smads can be divided
into 3 groups on the basis of their structure and function: the receptor-activated Smads,
including Smads 1 to 3, 5, and 8; the common-partner Smads, including Smad4, Medea, and
Sma-4; and the inhibitory Smads, including Smads 6/7 and Dad.14,16,38–41 Smads mediate
the signaling of several different members of the TGF-β superfamily.14,15,42 Activation of
TGF-β receptor-I leads to phosphorylation of receptor-activated Smads (Smad2 and Smad3),
which form a complex with Smad4, a common-partner Smad. The Smad2/3-Smad4 complex
translocates into the nucleus and activates target genes that negatively regulate the cell cycle.
16 Smad7, an inhibitory Smad, associates stably with the TGF-β receptor complex and inhibits
TGF-β–dependent phosphorylation of Smad2 and Smad3.14,19
In the present study, we delivered the Smad7 gene by an adenoviral vector to overexpress
Smad7 in the liver (Fig. 2). Without Smad7 gene delivery, liver regeneration was inhibited in
quarter-size liver grafts, as shown by suppression of BrdU incorporation, PCNA expression,
and graft weight gain (Fig. 3 and Fig. 4). Suppression of liver regeneration was associated with
translocation of phosphorylated Smad2/3 to the nucleus (Fig. 6). Gene delivery of Smad7
largely blocked Smad2/3 activation and nuclear translocation (Fig. 6) and markedly improved
the regeneration and functional recovery of quarter-size liver grafts (Fig. 3, Fig. 4, and Fig. 5).
These results are consistent with the conclusion that TGF-β/Smad signaling plays an important
role in the suppression of regeneration of small-for-size liver grafts.
SnoN is a negative regulator of TGF-β signaling. Therefore, we investigated whether Ad-
Smad7 exerts it effects by increasing SnoN. To the contrary, we observed an increase in SnoN
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in small-for-size grafts that was decreased by Ad-Smad7. Therefore, prevention of the
suppression of small-for-size liver graft regeneration by Ad-Smad7 is not mediated by
increasing nuclear SnoN. The relation of SnoN and TGF-β is complex. In the absence of TGF-
β, SnoN interacts directly with Smad2/Smad3-Smad4 complexes and recruits the nuclear
hormone receptor corepressor/mSin3A/histone deacetylase complex to Smads, thus repressing
TGF-β signaling.24,43 With TGF-β treatment, SnoN is rapidly degraded via the ubiquitin-
proteasome pathway,44,45 and this leads to the dissociation of SnoN from the Smads, thus
allowing the TGF-β signal to pass through. However, a longer TGF-β treatment induces SnoN
messenger RNA and increases SnoN expression46; this indicates that TGF-β signaling also
controls SnoN expression. This may exert a negative feedback to limit TGF-β’s effects.
Increased SnoN expression in small-for-size grafts may reflect a response of the liver to
increased TGF-β levels in an attempt to limit TGF-β’s effects. Because Smad7 blocks TGF-
β signaling, it likely also decreases TGF-β–dependent induction of SnoN.
Role of CDKIs in the Suppression of Regeneration of Small-for-Size Liver Grafts
Progress through the cell cycle is controlled by cyclins and protein kinase complexes of CDKs,
which phosphorylate their downstream targets on serines and threonines.47,48 Cyclin/CDKs
hyperphosphorylate retinoblastoma gene products, leading to the transcription of a number of
genes required for cell cycle progression.49,50 CDKIs inhibit cyclin/CDKs, leading to cell cycle
arrest. In some cells, TGF-β up-regulates the expression of the CDKIs p15Ink4B, p27Kip1,
and p21Cip1.36,51 p21Cip1, a potent universal growth inhibitor, forms complexes with cyclin
D–Cdk4/6, cyclin E–Cdk2, and cyclin A–Cdk2 to inhibit their activities.52,53 Expression of
p21Cip1 depends on p53 in some cell lines but is independent of p53 in some other cell lines.
54–57
In this study, we investigated the effects of Ad-Smad7 on CDKI expression after LT. CDKIs
p27Kip1, p15Ink4B, and p16Ink4A were not different between sham-operated livers, full-size
liver grafts, and quarter-size grafts (Fig. 7A). By contrast, p21Cip1was barely detectable in
sham-operated livers and full-size grafts but increased markedly in quarter-size grafts (Fig. 7).
After treatment with Ad-Smad7 to block TGF-β/Smad signaling, expression of p21Cip1 was
blunted (Fig. 7A,B). Expression of p53 was not altered in all groups studied. These results
indicate that TGF-β inhibits regeneration of small-for-size liver grafts, most likely by up-
regulating CDKI p21Cip1 in a p53-independent manner. This up-regulation of p21Cip1 by
TGF-β is mediated by the Smad signaling pathway.
Taken together, our results indicate that TGF-β increases after the transplantation of small-for-
size liver grafts and likely plays an important role in the suppression of liver regeneration.
Failure of liver regeneration is likely mediated by activation of the Smad signaling pathway
that up-regulates CDKI p21Cip1, leading to cell cycle arrest. Therefore, anti–TGF-β therapy
holds promise as a new strategy for improving the regeneration of small-for-size grafts
clinically. However, TGF-β is a cytokine that has a variety of physiological and
pathophysiological effects. Although inhibition of TGF-β could be therapeutic for some
situations in which overproduction of TGF-β leads to diseases (eg, liver fibrosis and suppressed
liver regeneration after massive liver resection and small-for-size LT), caution should be paid
to the potential adverse effects of overexpression of Smad7 related to the beneficial effects of
TGF-β, such as wound healing and suppression of tumor growth, especially in small-for-size
LT patients with a previous history of hepatic carcinoma because a previous study showed that
small-for-size LT increases the risk of tumor invasion and migration.58 In our short-term
studies, we did not observe adverse effects. However, long-term survival studies would be
needed in the future to investigate any potential adverse effects of overexpression of Smad7.
Because protein expression of adenoviral gene delivery peaks at 2 to 3 days, whereas TGF-β
increases within 18 hours after small-for-size LT, delivery of Ad-Smad7 at the same time as
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LT or after small-for-size syndrome develops would likely not achieve protection as
satisfactory as that achieved by predelivery of the gene. Nonetheless, our study illustrates the
important role played by TGF-β in the suppression of regeneration of small-for-size liver grafts.
On the basis of this observation, TGF-β inhibitors and neutralizing antibodies may prove to be
effective as therapy against small-for-size liver syndrome. Future studies will be needed to
determine the appropriate dose and time frame for such therapeutic use of TGF-β inhibitors.
Abbreviations
Ad-LacZ adenovirus carrying LacZ
Ad-Smad7 adenovirus carrying human Smad7
BrdU 5-bromo-2′-deoxyuridine
CDK cyclin-dependent kinase
CDKI cyclin-dependent kinase inhibitor
EGF epidermal growth factor
HA hemagglutinin
HGF hepatic growth factor
IL-6 interleukin 6
LT liver transplantation
p53 tumor protein p53
PCNA proliferating cell nuclear antigen
SnoN Ski-like oncogene
TGF transforming growth factor
TNFα tumor necrosis factor-α
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TGF-β1 production increased after partial liver transplantation. Livers were harvested at 1.5,
5, 18, and 38 hours after full-size (100%, n = 4), half-size (50%, n = 4), and quarter-size (25%,
n = 5) liver transplantation, and total TGF-β1 was determined. Values are means and standard
errors of the mean (P < 0.001 by 2-way analysis of variance). aP < 0.001 versus full-size grafts
and bP < 0.001 versus half-size grafts.
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Efficiency of adenoviral transfection. Livers were harvested 3 days after the injection of normal
saline, Ad-LacZ, or Ad-Smad7. (A) β-Galactosidase was detected immunohistochemically (n
= 4 per group). The left panel shows a liver from a saline-treated rat; the right panel shows a
liver from an Ad-LacZ–treated rat. The bar represents 20 µm. (B) The HA tag of Smad7 and
Smad7 were detected by western blotting in comparison with actin (n = 3 per group).
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Ad-Smad7 reverses the suppression of cell proliferation in small-for-size liver grafts. Livers
were transplanted 3 days after adenoviral infection, and they were harvested 38 hours after
implantation or a sham operation for immunohistochemical detection of BrdU, as described in
the Materials and Methods section. The upper left panel shows a liver from a sham-operated
rat treated with Ad-LacZ, the upper right panel shows a full-size graft (100%) from a donor rat
treated with Ad-LacZ, the middle left panel shows a half-size graft (50%) from a donor rat
treated with Ad-LacZ, the middle right panel shows a quarter-size graft (25%) from a donor
rat treated with saline, the lower left panel shows a quarter-size graft from a donor rat treated
with Ad-LacZ, and the lower right panel shows a quarter-size graft from a donor rat treated
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with Ad-Smad7. Note the marked increase of BrdU incorporation (black nuclear labeling) in
the half-size graft (middle left) compared to the sham-operated liver or full-size liver grafts
(upper left and right); this was suppressed in quarter-size grafts after Ad-LacZ or saline
treatment (lower left and middle right). Donor treatment with Ad-Smad7 markedly increased
BrdU incorporation after quarter-size transplantation (lower right). The bar represents 50 µm.
n = 4 per group.
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Liver regeneration is suppressed in quarter-size liver grafts: reversal by Ad-Smad7. The
conditions were the same as those for Fig. 3. (A) BrdU labeling, (B) PCNA labeling, and (C)
the increase in the graft weight at 38 hours after transplantation were determined as described
in the Materials and Methods section. (A,C) The values are means and standard errors of the
mean, and differences between groups were tested by 1-way analysis of variance (P < 0.001
for panels A and C, n = 4 per group). aP < 0.001 versus full-size grafts (100%), bP < 0.001
versus half-size grafts (50%), and cP < 0.001 versus quarter-size grafts (25%) treated with
saline or Ad-LacZ. (B) The values are 25th percentiles, medians, and 75th percentiles, and
differences between groups were tested by the Kruskal-Wallis test (P < 0.001, n = 4 per
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group). aP < 0.05 versus full-size grafts (100%), bP < 0.05 versus half-size grafts (50%),
and cP < 0.05 versus quarter-size grafts (25%) treated with saline or Ad-LacZ. Differences in
BrdU incorporation, PCNA expression, and graft weight between quarter-size grafts treated
with saline and Ad-LacZ were not statistically significant.
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Ad-Smad7 protects against hyperbilirubinemia after the transplantation of quarter-size liver
grafts. Blood samples were collected at 18, 24, and 38 hours after implantation for bilirubin
measurement. Values are means and standard errors of the mean. Differences among groups
were tested by 2-way analysis of variance (P < 0.001, n = 4 per group). aP < 0.001 versus full-
size (100%) grafts from Ad-LacZ–treated donor rats and bP < 0.001 versus quarter-size (25%)
grafts from donor rats treated with Ad-LacZ. Differences in total bilirubin between recipients
of quarter-size grafts treated with saline and Ad-LacZ were not statistically significant.
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Ad-Smad7 prevents Smad2/3 nuclear translocation in quarter-size liver grafts. The conditions
were the same as those for Fig. 3. (A) Phosphorylated Smad2/3 was detected
immunohistochemically (n = 4 per group), as described in the Materials and Methods section.
The upper left panel shows a liver from a sham-operated donor rat treated with Ad-LacZ, the
upper right panel shows a full-size graft (100%) from a rat treated with Ad-LacZ, the middle
left panel shows a half-size graft (50%) from a rat treated with Ad-LacZ, the middle right panel
shows a quarter-size graft (25%) from a rat treated with saline, the lower left panel shows a
quarter-size graft from a rat treated with Ad-LacZ, and the lower right panel shows a quarter-
size graft from a rat treated with Ad-Smad7. Note that black immunoreactivity for
Zhong et al. Page 20













phosphorylated Smad2/3 in nuclei increased in quarter-size grafts (25%) compared to sham-
operated livers and full-size (100%) and half-size (50%) liver grafts. Ad-Smad7 treatment
decreased phosphorylated Smad2/3 labeling in quarter-size grafts. The bar represents 50 µm.
(B) SnoN and actin in liver tissue were detected by western blotting (n = 4 per group), and
representative images are shown.
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p21Cip1 expression is suppressed after transplantation of quarter-size liver grafts: reversal by
Ad-Smad7. Liver grafts were harvested at 38 hours after implantation, and p21Cip1, p27Kip1,
p15Ink4B, p53, and actin were detected by western blotting, as described in the Materials and
Methods sections. (A) Representative gels (n = 4 per group). (B) Plots of p21Cip1/actin ratios
(means and standard errors of the mean) determined by densitometry (P < 0.001 by 1-way
analysis of variance, n = 4 per group). aP < 0.001 versus the sham operation, bP < 0.001 versus
the full-size grafts (100%) from Ad-LacZ–treated donors, cP < 0.001 versus the quarter-size
grafts (25%) from Ad-LacZ–treated donors, and dP = 0.042 versus the sham operation.
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